News and Press Releases
Lindus Health and Thirty Madison complete enrolment of personalised dermatology care pilot study
14 December 2023 -- London, UK -- Clinical trial company Lindus Health and Thirty Madison, a US-based family of specialised healthcare brands, have today announced the completion of enrolment of...
Category: Clinical Trials
Posted: December 14, 2023
PlaqueTec recruits first ten patients in BIOPATTERN trial
Trial to investigate atherosclerotic cardiovascular diseases receives MHRA approval to continue recruitment towards 300-patient target Unique PlaqueTec Liquid Biopsy System will be used to collect blood samples containing biomolecules localising...
Category: Clinical Trials
Posted: November 29, 2023
Exonate announces successful completion of phase 1b/2a trial in diabetic macular oedema
Lead ophthalmology candidate EXN407 has potential to be the first topical treatment for diabetic retinopathy/diabetic macular oedema EXN407 met all endpoints and displayed encouraging biological activity in diabetic patients with...
Category: Clinical Trials
Posted: November 28, 2023
Vaccitech Renames as Barinthus Biotherapeutics to Highlight Strategic Evolution into a T-Cell Immunotherapy Company Targeting Chronic Infectious Diseases, Autoimmunity and Cancer
New Corporate Brand to be Unveiled at AASLD Liver Meeting® 2023 with Interim Data 6 November 2023 -- Oxford, UK -- Barinthus Biotherapeutics, formerly Vaccitech, a clinical-stage biopharmaceutical company developing novel...
Category: Drug Discovery
Posted: November 27, 2023
Janssen Submits Application to the European Medicines Agency forRYBREVANT▼ (amivantamab) in Combination with Chemotherapy for the Treatment of Adult Patients with Advanced EGFR-Mutated Non-Small Cell Lung Cancer After Failure of Prior Therapy
The submission is supported by data from the Phase 3 MARIPOSA-2 study featured in a Late-Breaking Presidential Symposium session at the 2023 ESMO Congress and simultaneously published in Annals of...
Category: Clinical Trials
Posted: November 23, 2023
Janssen-Cilag Limited 50-100 Holmers Farm Way High Wycombe Buckinghamshire HP12 4EG
Commercial study set up times reduced by a third, according to new data
26 October 2023 -- London, England -- New data from the National Institute for Health and Care Research (NIHR) shows that the National Contract Value Review has significantly reduced the...
Category: Clinical Trials
Posted: October 26, 2023
Landmark Phase 3 MARIPOSA Study Shows RYBREVANT▼(amivantamab) Plus Lazertinib Resulted in 30% Reduction in Risk of Disease Progression or Death Compared to Osimertinib in Patients with EGFR-Mutated NSCLC
Early data show an overall survival trend favoring the combination of amivantamab and lazertinib compared to osimertinib; consistent results seen in patients with and without brain metastases Late-breaking results from...
Category: Clinical Trials
Posted: October 24, 2023
Janssen-Cilag Limited 50-100 Holmers Farm Way High Wycombe Buckinghamshire HP12 4EG
Results from Phase 2 THOR-2 Study Showed Improved Rates of Recurrence-Free Survival in Patients with High-Risk Non-Muscle-Invasive Bladder Cancer with Select Fibroblast Growth Factor Receptor Alterations Treated with Erdafitinib Versus Chemotherapy
Data from Cohort 1 of the phase 2 THOR-2 study showed oral erdafitinib reduced the risk of disease recurrence or death compared with intravesical standard-of-care chemotherapy 21 October 2023 --...
Category: Clinical Trials
Posted: October 23, 2023
Janssen-Cilag Limited 50-100 Holmers Farm Way High Wycombe Buckinghamshire HP12 4EG
European Commission Approves ADCETRIS (brentuximab vedotin) for the Treatment of Adult Patients with Previously Untreated CD30+ Stage III Hodgkin Lymphoma in Combination with AVD
· Approval Based on Updated Positive Overall Survival Results from the phase 3 ECHELON-1 Study for Stage III & IV Hodgkin Lymphoma · First Significant Improvement in Overall Survival in Two Decades...
Category: Pharmaceutical
Posted: October 23, 2023
AstraZeneca reinforces commitment to protecting the most vulnerable from serious infectious diseases at IDWeek 2023
Real-world data from INFORM study demonstrate increased risk of severe COVID-19 outcomes among all individuals with immunocompromising conditions and highlight need for additional protection FluMist Quadrivalent data support the potential...
Category: Clinical Trials
Posted: October 12, 2023
PLC 1 Francis Crick Avenue Cambridge Biomedical Campus Cambridge CB2 0AA UK
MSD’s WELIREG▼(belzutifan) made available for the treatment of eligible adults with von Hippel-Lindau (VHL) disease in Scotland
Scotland is the first European country to accept belzutifan as a treatment for adult patients with von Hippel-Lindau (VHL) disease who require therapy for VHL-associated renal cell carcinoma (RCC), central...
Category: Pharmaceutical
Posted: October 9, 2023
1 rue Jacques Monod, Site Montesquieu, 33650 Martillac, France
Moderna Announces Positive Phase 1/2 Data from mRNA-1083, the Company’s Combination Vaccine Against Influenza and COVID-19
mRNA-1083 showed strong immunogenicity against influenza and COVID-19, with an acceptable reactogenicity and safety profile, compared to licensed standalone vaccines Company to begin phase 3 trial of mRNA-1083 in adults...
Category: Clinical Trials, Drug Discovery
Posted: October 4, 2023
Signant Health Launches Signant Biotech to Accelerate and Streamline Clinical Development for Emerging Biopharmaceutical Organisations
3 October 2023 -- Philadelphia, US -- Signant Health, the leader in evidence generation for modern clinical trials, announced today the launch of Signant Biotech – an integrated clinical research...
Category: Clinical Trials
Posted: October 4, 2023
Shionogi Presents New Ensitrelvir Clinical and Real-World Data Reinforcing Potential Across COVID-19 Populations at ESWI 2023
New exploratory analysis of phase 3 SCORPIO-SR study data in Asia suggests that ensitrelvir may reduce the risk of persistent and new late-onset symptoms associated with long COVID-19 over one...
Category: Clinical Trials
Posted: September 20, 2023
Mural Health Raises $8m Led by Bessemer Venture Partners to Accelerate Growth
Funding enables Mural Health to expand its Mural Link platform to modernise the clinical trial participant experience 19 September 2023 -- Pennsylvania, US -- Mural Health Technologies, a next-generation clinical...
Category: Clinical Trials
Posted: September 20, 2023
